Back to GetFilings.com



Table of Contents
 
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
 

 
FORM 10-Q
 
x
 
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (D) OF THE SECURITIES EXCHANGE ACT OF 1934.
 
For the quarterly period ended September 30, 2002.
 
¨
 
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934.
 
For the transition period from                              to                             .
 
Commission File Number
0-25133
 

 
PHARMANETICS, INC.
(Exact Name of Registrant as Specified in its Charter)
 
North Carolina
 
56-2098302
(State or other jurisdiction of
Incorporation or organization)
 
(IRS Employer Identification Number)
 
9401 Globe Center Drive, Suite 140
Morrisville, North Carolina
 
27560
(Address of Principal Executive Office)
 
(Zip Code)
 
Registrant’s Telephone Number, Including Area Code 919-582-2600
 

 
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    YES  x  NO  ¨
 
Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.
 
Class

 
Outstanding as of November 8, 2002

Common Stock, no par value
 
9,610,070


Table of Contents
 
PHARMANETICS, INC.
 
INDEX TO FORM 10-Q
 
              
PAGE

PART I.
  
FINANCIAL INFORMATION
    
    
Item 1.
  
Financial Statements
    
            
3
            
4
            
5
            
6
    
Item 2.
     
8
    
Item 3.
     
12
    
Item 4.
     
12
PART II.
  
OTHER INFORMATION
    
    
Item 6.
     
13
  
14
CERTIFICATIONS
    


Table of Contents
 
PHARMANETICS, INC.
CONSOLIDATED BALANCE SHEETS
(In thousands, except share data)
 
    
September 30, 2002

    
December 31, 2001

 
    
(Unaudited)
        
ASSETS
                 
Current assets:
                 
Cash and cash equivalents
  
$
8,721
 
  
$
14,883
 
Accounts and other receivables
  
 
825
 
  
 
462
 
Inventories
  
 
2,434
 
  
 
2,223
 
Other current assets
  
 
355
 
  
 
242
 
    


  


Total current assets
  
 
12,335
 
  
 
17,810
 
Property and equipment, net
  
 
8,373
 
  
 
8,503
 
Patents and intellectual property, net
  
 
559
 
  
 
551
 
Other noncurrent assets
  
 
93
 
  
 
150
 
    


  


Total assets
  
$
21,360
 
  
$
27,014
 
    


  


                   
                   
LIABILITIES, CONVERTIBLE REDEEMABLE PREFERRED STOCK, CONTINGENTLY REDEEMABLE COMMON STOCK AND SHAREHOLDERS’ EQUITY
                 
Current liabilities:
                 
Accounts payable
  
$
482
 
  
$
741
 
Accrued expenses
  
 
665
 
  
 
723
 
Deferred revenue, current portion
  
 
709
 
  
 
487
 
Current portion of long-term debt and capital lease obligations
  
 
29
 
  
 
23
 
    


  


Total current liabilities
  
 
1,885
 
  
 
1,974
 
    


  


Noncurrent liabilities:
                 
Deferred revenue, less current portion
  
 
2,257
 
  
 
1,346
 
Long-term debt and capital lease obligations, less current portion
  
 
55
 
  
 
66
 
    


  


Total noncurrent liabilities
  
 
2,312
 
  
 
1,412
 
    


  


Total liabilities
  
 
4,197
 
  
 
3,386
 
Series A convertible redeemable preferred stock, no par value; authorized 120,000 shares; 90,500 shares issued and outstanding at September 30, 2002 and December 31, 2001 (aggregate liquidation value at September 30, 2002 of $9,050)
  
 
7,520
 
  
 
7,520
 
Contingently redeemable common stock
  
 
13,376
 
  
 
8,538
 
Shareholders’ equity:
                 
Common stock, no par value; authorized 40,000,000 shares; 9,610,070 and 9,485,294 issued and outstanding at September 30, 2002 and December 31, 2001, respectively
  
 
52,985
 
  
 
57,186
 
Accumulated deficit
  
 
(56,718
)
  
 
(49,616
)
    


  


Total shareholders’ equity
  
 
(3,733
)
  
 
7,570
 
    


  


Total liabilities, convertible redeemable preferred stock,contingently redeemable common stock and shareholders’ equity
  
$
21,360
 
  
$
27,014
 
    


  


 
The accompanying notes are an integral part of the unaudited consolidated financial statements

3


Table of Contents
 
PHARMANETICS, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)
(In thousands, except per share data)
 
    
Three Months Ended

    
Nine Months Ended

 
    
September 30
2002

    
September 30
2001

    
September 30
2002

    
September 30
2001

 
Net sales
  
$
1,176
 
  
$
1,235
 
  
$
2,918
 
  
$
3,359
 
Cost of goods sold
  
 
922
 
  
 
1,004
 
  
 
2,548
 
  
 
2,865
 
    


  


  


  


Gross profit
  
 
254
 
  
 
231
 
  
 
370
 
  
 
494
 
    


  


  


  


Operating expenses:
                                   
General and administrative
  
 
808
 
  
 
1,094
 
  
 
2,610
 
  
 
3,322
 
Sales and marketing
  
 
281
 
  
 
336
 
  
 
816
 
  
 
928
 
Research and development
  
 
1,475
 
  
 
1,007
 
  
 
4,139
 
  
 
2,752
 
    


  


  


  


Total operating expenses
  
 
2,564
 
  
 
2,437
 
  
 
7,565
 
  
 
7,002
 
    


  


  


  


Operating loss
  
 
(2,310
)
  
 
(2,206
)
  
 
(7,195
)
  
 
(6,508
)
Other income (expense):
                                   
Interest expense
  
 
(2
)
  
 
(3
)
  
 
(7
)
  
 
(69
)
Interest income
  
 
25
 
  
 
138
 
  
 
105
 
  
 
347
 
Grant/royalty income
  
 
—  
 
  
 
—  
 
  
 
25
 
  
 
12
 
Development income
  
 
131
 
  
 
50
 
  
 
359
 
  
 
150
 
Other expense
  
 
(29
)
  
 
(5
)
  
 
(51
)
  
 
(52
)
    


  


  


  


Total other income
  
 
125
 
  
 
180
 
  
 
431
 
  
 
388
 
    


  


  


  


Net and comprehensive loss
  
 
(2,185
)
  
 
(2,026
)
  
 
(6,764
)
  
 
(6,120
)
Dividends on preferred stock
  
 
108
 
  
 
134
 
  
 
337
 
  
 
425
 
    


  


  


  


Net loss applicable to common shareholders
  
$
(2,293
)
  
$
(2,160
)
  
$
(7,101
)
  
$
(6,545
)
    


  


  


  


Basic and diluted net loss per common share
  
$
(0.24
)
  
$
(0.23
)
  
$
(0.74
)
  
$
(0.75
)
    


  


  


  


Weighted average common shares outstanding
  
 
9,578
 
  
 
9,369
 
  
 
9,552
 
  
 
8,694
 
    


  


  


  


 
The accompanying notes are an integral part of the unaudited consolidated financial statements.

4


Table of Contents
 
PHARMANETICS, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)
(In thousands)
 
    
Nine Months Ended

 
    
September 30,
2002

    
September 30,
2001

 
Cash flows from operating activities:
                 
Net loss
  
$
(6,764
)
  
$
(6,120
)
Adjustments to reconcile net loss to net cash used in operating activities:
                 
(Gain) Loss on sale of property and equipment
  
 
(1
)
  
 
49
 
Depreciation
  
 
1,136
 
  
 
925
 
Amortization of intangible and other assets
  
 
110
 
  
 
144
 
Amortization of discount on investments
  
 
—  
 
  
 
(31
)
Loss on trading securities
  
 
53
 
  
 
5
 
Provision for inventory obsolescence
  
 
303
 
  
 
110
 
Change in operating assets and liabilities:
                 
Accounts receivable
  
 
(363
)
  
 
(43
)
Inventories
  
 
(514
)
  
 
(816
)
Other current and non-current assets
  
 
(165
)
  
 
(60
)
Accounts payable and accrued expenses
  
 
(318
)
  
 
(733
)
Deferred revenue
  
 
1,132
 
  
 
326
 
    


  


Net cash used in operating activities
  
 
(5,391
)